Acumen Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Acumen Pharmaceuticals
ABOS Stock  USD 1.50  0.02  1.35%   
Acumen Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Acumen Pharmaceuticals' valuation are provided below:
Gross Profit
-106.6 M
Market Capitalization
89.6 M
Enterprise Value Revenue
89.674
Revenue
329 K
Earnings Share
(1.94)
There are over one hundred nineteen available fundamental signals for Acumen Pharmaceuticals, which can be analyzed over time and compared to other ratios. All traders should validate Acumen Pharmaceuticals' prevailing fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 112.8 M in 2025. Enterprise Value is likely to drop to about 106.3 M in 2025
Check Acumen Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Acumen Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 10.8 M, Interest Income of 15 M or Depreciation And Amortization of 169.1 K, as well as many indicators such as Price To Sales Ratio of 482, Dividend Yield of 0.0 or PTB Ratio of 0.6. Acumen financial statements analysis is a perfect complement when working with Acumen Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Acumen Stock
Check out the analysis of Acumen Pharmaceuticals Correlation against competitors.
For more information on how to buy Acumen Stock please use our How to Invest in Acumen Pharmaceuticals guide.

Acumen Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets188.4 M239 M80.1 M
Slightly volatile
Other Current Liabilities22.9 M21.8 M5.1 M
Slightly volatile
Total Current Liabilities29 M27.6 M6.4 M
Slightly volatile
Accounts Payable5.9 M5.6 M1.2 M
Slightly volatile
Cash33.8 M35.6 M31.1 M
Slightly volatile
Non Currrent Assets Other251.2 K379 K169 K
Slightly volatile
Cash And Short Term Investments153.5 M171.6 M65.6 M
Slightly volatile
Common Stock Shares Outstanding47 M60 M41.5 M
Slightly volatile
Liabilities And Stockholders Equity188.4 M239 M80.1 M
Slightly volatile
Non Current Liabilities Total18.6 M29.6 M19.7 M
Pretty Stable
Inventory118.3 K112.7 K56.9 K
Slightly volatile
Other Current Assets3.3 M6.4 M2 M
Slightly volatile
Other Stockholder Equity330 M507 M147.5 M
Slightly volatile
Total Liabilities35.8 M57.2 M25 M
Slightly volatile
Total Current Assets156.8 M178.3 M67.3 M
Slightly volatile
Net Working Capital145.6 M150.7 M62 M
Slightly volatile
Short and Long Term Debt Total16.1 M29.7 M4.8 M
Slightly volatile
Common Stock Total Equity3.2 K3.6 K3.9 K
Slightly volatile
Capital Surpluse392.1 M413.9 M360.1 M
Slightly volatile
Short Term Debt252.7 K266 K258 K
Slightly volatile
Common Stock5.5 K6.9 K4.4 K
Slightly volatile
Property Plant Equipment110.5 K189.8 K66.4 K
Slightly volatile
Long Term Debt30.7 M28.4 M27.6 M
Slightly volatile
Intangible Assets97.6 K75 K158.7 K
Slightly volatile

Acumen Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income10.8 M10.2 M2 M
Slightly volatile
Interest Income15 M14.3 M2.5 M
Slightly volatile
Depreciation And Amortization169.1 K178 K5.4 M
Slightly volatile
Selling General Administrative11.3 M20.2 M5.1 M
Slightly volatile
Other Operating Expenses119.7 M114 M29 M
Slightly volatile
Research Development98.5 M93.8 M23.3 M
Slightly volatile
Cost Of Revenue51.1 M48.7 M8.9 M
Slightly volatile
Total Operating Expenses119.7 M114 M26.9 M
Slightly volatile
Selling And Marketing Expenses147.2 K165.6 K180.6 K
Slightly volatile

Acumen Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation10.1 M9.6 M2 M
Slightly volatile
Change In Working Capital12.2 M11.7 M2.5 M
Slightly volatile
Begin Period Cash Flow69.1 M67.1 M31.9 M
Slightly volatile
Depreciation99.5 K178 K42.4 K
Slightly volatile
Capital Expenditures15.2 K16 K43.3 K
Very volatile
Issuance Of Capital Stock7.5 M7.9 M28.2 M
Slightly volatile
Total Cash From Financing Activities6.6 M6.9 M29.8 M
Slightly volatile
End Period Cash Flow34.1 M35.9 M31.2 M
Slightly volatile
Change To Liabilities3.1 M2.9 M820 K
Slightly volatile
Cash And Cash Equivalents Changes6.8 M7.1 M60.7 M
Slightly volatile
Cash Flows Other Operating1.3 M1.4 M58.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio482461456
Slightly volatile
Days Sales Outstanding13.6624.9313.3711
Slightly volatile
Stock Based Compensation To Revenue0.080.09650.1019
Slightly volatile
Capex To Depreciation0.08540.08990.7921
Slightly volatile
EV To Sales463426443
Slightly volatile
Payables Turnover29.027.625.4884
Slightly volatile
Sales General And Administrative To Revenue0.590.850.6662
Slightly volatile
Research And Ddevelopement To Revenue4.255.015.1295
Very volatile
Cash Per Share3.152.85871.7655
Slightly volatile
Days Payables Outstanding12.9913.687.9 K
Slightly volatile
Income Quality0.840.84250.8215
Pretty Stable
Current Ratio6.146.45879.6099
Slightly volatile
Receivables Turnover14.3915.1540.494
Slightly volatile
Debt To Equity0.170.16340.028
Slightly volatile
Capex Per Share3.0E-43.0E-40.0018
Slightly volatile
Revenue Per Share0.0370.04510.0441
Slightly volatile
Interest Debt Per Share0.310.56270.0941
Slightly volatile
Debt To Assets0.130.12430.0221
Slightly volatile
Operating Cycle13.6624.9313.3711
Slightly volatile
Days Of Payables Outstanding12.9913.687.9 K
Slightly volatile
Ebt Per Ebit1.790.89751.2928
Pretty Stable
Long Term Debt To Capitalization0.0960.13930.096
Slightly volatile
Total Debt To Capitalization0.150.14040.0246
Slightly volatile
Debt Equity Ratio0.170.16340.028
Slightly volatile
Quick Ratio6.146.45879.6099
Slightly volatile
Net Income Per E B T0.790.890.975
Slightly volatile
Cash Ratio1.231.29056.4852
Pretty Stable
Days Of Sales Outstanding13.6624.9313.3711
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.00021.0082
Slightly volatile
Debt Ratio0.130.12430.0221
Slightly volatile
Price Sales Ratio482461456
Slightly volatile
Asset Turnover0.03530.03720.1575
Slightly volatile
Gross Profit Margin1.091.141.0098
Slightly volatile

Acumen Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap112.8 M118.7 M583.5 M
Slightly volatile
Enterprise Value106.3 M111.9 M559.7 M
Slightly volatile

Acumen Fundamental Market Drivers

Cash And Short Term Investments171.6 M

Acumen Upcoming Events

25th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
25th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Acumen Pharmaceuticals Financial Statements

Acumen Pharmaceuticals shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Acumen Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Acumen Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Acumen Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Cost Of Revenue48.7 M51.1 M
Stock Based Compensation To Revenue 0.10  0.08 
Sales General And Administrative To Revenue 0.85  0.59 
Research And Ddevelopement To Revenue 5.01  4.25 
Revenue Per Share 0.05  0.04 
Ebit Per Revenue(6.34)(6.65)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Acumen Stock Analysis

When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY